11-Hydroxycannabinol

From WikiMD's WELLNESSPEDIA

Chemical structure of 11-Hydroxycannabinol

11-Hydroxycannabinol (11-OH-CBN) is a cannabinoid metabolite that is formed in the body after the consumption of cannabis. It is a hydroxylated form of cannabinol (CBN), which itself is a degradation product of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Chemical Structure[edit]

11-Hydroxycannabinol is characterized by the addition of a hydroxyl group (-OH) at the 11th carbon position of the CBN molecule. This modification alters the chemical properties and biological activity of the compound compared to its parent molecule, CBN.

Pharmacology[edit]

11-Hydroxycannabinol is known to interact with the endocannabinoid system, specifically binding to cannabinoid receptors such as CB1 and CB2. These interactions can influence various physiological processes, including mood, appetite, and pain perception.

Metabolism[edit]

In the human body, 11-Hydroxycannabinol is produced primarily in the liver through the action of cytochrome P450 enzymes on CBN. This metabolic pathway is similar to the conversion of THC to 11-Hydroxy-THC, another active metabolite.

Biological Effects[edit]

The biological effects of 11-Hydroxycannabinol are not as well-studied as those of THC or CBN. However, it is believed to have a lower psychoactive potency compared to THC. Its effects on the body may include mild sedation and analgesia, but further research is needed to fully understand its pharmacological profile.

Related Compounds[edit]

Related Pages[edit]

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.